For example, MRT‐2359 is a GSPT1‐TPD currently evaluated in phase 1 trials to target Myc‐amplified tumours, a context where all previous SMI—such as bromodomain extra‐terminal inhibitors—have failed. Here, MYC is linked to neoplasm.